Leukämien | ICD10: C91-C96

192 kB  

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

241 kB  

A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

43 kB  

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication

147 kB  

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

166 kB  

Phase Ib/IIa study of palbociclib in MLL-rearranged Acute Leukemias

17.0 kB  

Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leukämie und verwandten Vorläufer- Neoplasien und der akuten Leukämie unklarer Linienzugehörigkeit: Das AMLSG Biology and Outcome (BiO)-Projekt

191 kB  

Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy

161 kB  

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

171 kB  

Eine randomisierte Phase-III-Studie zum Vergleich von Arsentrioxid (ATO) in Verbindung mit ATRA und Idarubicin versus ATRA in Kombination mit einer Anthracyclin-basierten Chemotherapie (AIDA) bei Patienten mit neu diagnostizierter, akuter Promyelozytenleukämie mit Hochrisikomerkmalen

188 kB  

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

190 kB  

An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated and / or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients With mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)

164 kB  

A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to ConSolidation Therapy in AML patients

98 kB  

Multizentrische, offene einarmige Phase II Studie, welche die Verträglichkeit und Wirksamkeit von Bosutinib mit initialer langsamer Dosissteigerung testet bei CML-Patienten, die sich refraktär oder intolerant auf eine Therapie mit Nilotinib oder Dasatinib gezeigt haben

149 kB  

Patienten mit CML in der chronische Phase unter Dasatinib Therapie

265 kB  

A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors

161 kB  

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

202 kB  

A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID

151 kB  

Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

237 kB  

A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)

160 kB  

Efficacy and Safety of Thrombopoetin-Receptor Agonist Eltrombopag in in Combination With Ciclosporin A in Moderate Aplastic Anemia (EMAA): Prospective Randomized Multicenter Study

619 kB  

Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase II, Multicenter Trial With Post-study Follow-up

159 kB  

Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie

48 kB  

GMALL-REGISTER Nicht-interventionelle Studie mit begleitender Biomaterialbank

137 kB  

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

145 kB  

A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)

255 kB  

Multicenter Prospective Trial After First Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd Time

302 kB  

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients .18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

87 kB  

Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidin (Vidaza)

166 kB  

Ruxolitinib versus best available therapy in patients with high-risk polycytehemia vera or high-risk essential thrombocythemia

152 kB  

Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia < 60a

200 kB  

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients =65 Years of Age Not Eligible for Intensive Chemotherapy